"The Markush structures database has become a vital backbone of pharmaceutical research in the digital age," said Alex Drijver, CEO of ChemAxon. "By delivering this data directly to the end user in an intuitive, flexible format, our clients have access to the functionality and data necessary to stay competitive in today's fast-paced, complex marketplace."
The Thomson Reuters IP Data Feed - Markush Structures database is indexed from 550,000 patent families, plus 1.7 million related, exemplified, specific compounds. It includes patents for pharmaceuticals, agrochemicals and general chemistry spanning 26 patent-issuing authorities. Markush data is integrated with high-quality patent summary data from DWPI, enabling access to enhanced patent abstracts, family and assignee details, and relevant bibliographic data. For more information, contact Steve Hajkowski, product manager, Thomson Reuters, at email@example.com
About ChemAxon Ltd
ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and pro
|SOURCE Thomson Reuters|
Copyright©2010 PR Newswire.
All rights reserved